Vascular Occlusion: What Every Filler Patient Should Know

Vascular occlusion is the most serious complication of dermal filler treatment. It is rare. It is treatable when recognised early. Good technique and good protocols lower the risk considerably, though no clinic can remove it entirely. This article explains what it is, how to spot the warning signs, and what questions to ask before you book a filler appointment anywhere.

What is vascular occlusion?

Vascular occlusion occurs when filler material blocks or compresses a blood vessel, cutting off blood supply to the surrounding tissue. Without adequate blood flow, that tissue can begin to die within minutes.

In most cases the vessel involved is an artery supplying the skin. The result, if not treated immediately, is skin necrosis: a patch of tissue that turns dusky, then dark, and eventually breaks down. In rare cases involving the ophthalmic artery, the consequence can be permanent vision loss in one or both eyes.

It is one of the few cosmetic complications that is time-critical. Treatment needs to start immediately. The sooner the blockage is dissolved, the better the outcome, and every delay makes tissue damage harder to reverse.

How common is it?

Estimates vary depending on the source and the region of the face treated. A 2021 US study of 370 experienced dermatologists covering 1.7 million syringes of filler, recorded one occlusion for every 6,410 syringes injected with a needle and one for every 40,882 injected with a cannula. The complication is rare, but more than a quarter of those dermatologists had seen at least one.

What that statistic does not tell you is whether the clinic treating you has the training, the equipment and the emergency protocol to respond if you are the patient in whom it occurs. That question is where your due diligence should focus.

Why does it happen?

There are two mechanisms. The first is direct intravascular injection: the needle or cannula enters the blood vessel and the filler is placed inside it. The second is external compression: a bolus of filler deposited near a vessel squeezes it shut from outside. Both can produce the same clinical picture.

Certain areas of the face carry higher anatomical risk than others. The glabella, the zone between the eyebrows, has a dense arterial network and limited collateral blood supply. The nose, nasolabial folds, temples and lips also carry elevated risk. These are not areas to avoid entirely. They are areas where injector technique, depth of injection, choice of product and speed of delivery all matter more.

Which fillers can cause it?

Any injectable filler placed near a blood vessel can theoretically cause occlusion. In practice, hyaluronic acid (HA) fillers, the most widely used type, carry a significant safety advantage: they can be dissolved. Hyaluronidase, an enzyme administered by injection, breaks down HA filler rapidly. When given in adequate doses within the right timeframe, it is the primary treatment for HA-filler vascular occlusion and it works.

Non-HA fillers, including certain calcium hydroxylapatite, poly-L-lactic acid and permanent filler products, cannot be dissolved this way. A vascular occlusion involving one of these products presents a more difficult clinical situation, with fewer intervention options.

This is one reason why many clinicians working to a high safety standard use HA fillers as a default. The reversibility is not a footnote. It is a structural safety feature.

Warning signs: what to look for

The early signs of vascular occlusion appear during or immediately after injection. Recognising them requires training and experience. They include:

• Blanching: the skin turns white or pale at the injection site or along the path of a vessel. This is a key early sign and should cause injection to stop immediately.
• Livedo reticularis: a mottled, net-like pattern of skin discolouration, usually dusky red or purple, as blood flow is disrupted.
• Pain: disproportionate or unusual pain during or after injection, particularly in an area that should not be particularly sensitive.
• Capillary refill delay: the skin does not pink back quickly when pressed and released.
• Visual symptoms: blurred vision, double vision, sudden loss of visual field. These indicate possible ophthalmic involvement and are an emergency requiring immediate referral to A&E.

None of these signs requires a blood test or a scan to identify. A trained injector who knows what they are looking for can act within seconds. The time between recognising occlusion and beginning treatment with hyaluronidase is the variable that determines outcome.

What good emergency management looks like

A clinic operating to an appropriate safety standard will have:

1. Hyaluronidase on the premises, in date and in adequate quantity, at every filler appointment.
2. A clinician who has been trained specifically in the recognition and management of vascular occlusion, not just in injection technique.
3. A written emergency protocol that every member of staff is familiar with.
4. A clear escalation pathway for ophthalmic involvement, including the location of the nearest A&E with an ophthalmology unit.
5. Post-treatment monitoring time sufficient to observe for delayed signs.

If a clinic cannot confirm each of these five points, that is worth knowing before you book.

Questions to ask before any filler appointment

You are entitled to ask your clinic the following before agreeing to treatment. A clinic confident in its safety protocols will answer without hesitation.

• Do you hold hyaluronidase on site, and is it in date?
• Has the practitioner who will treat me received specific training in vascular occlusion management?
• What would happen if I experienced a reaction during or after my appointment today?
• Does the prescribing clinician oversee the injectable treatments delivered at this clinic?
• Are the fillers you use hyaluronic acid-based?

These are not difficult questions. They are reasonable. Any hesitation, evasiveness or irritation in response to them is itself informative.

What we do at The London Road Clinic

Our injectable treatments are overseen by Dr Shahe Boghossian (Medical Consultant, GMC 5204600), who brings a background in vascular surgery to our clinical governance. Hyaluronidase is held on-site and in date at every filler session. Our injectors hold specific training in vascular complication recognition and management, and our emergency protocol is reviewed at the clinical governance level.

We use hyaluronic acid-based fillers as standard. The reversibility of HA filler is, in our view, a clinical requirement rather than a preference.

All filler treatments at the clinic are preceded by an in-person consultation. Anatomy, risk profile, and medical history are assessed before any product is selected or volume agreed.

Frequently asked questions